OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
MODD55

Modern Diagnostic & Research Centre Ltd

Healthcare Facilities & ServicesVerified

Modern Diagnostic & Research Centre Ltd maintains a capital structure with a debt-to-equity ratio of 1.07, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.75, suggesting that its current liabilities exceed its current assets. Despite a net income of INR 89.68 million, the company reported negative free cash flow of INR 14,000, primarily due to a significant capital expenditure of INR 131.59 million. In terms of profitability, the company's return on equity (ROE) is 43.27%, and its return on assets (ROA) is 13.89%, both of which are strong indicators of efficient use of equity and assets. These figures suggest that the company is generating substantial returns relative to its equity and asset base, which is favorable compared to industry norms. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks if the primary segment faces challenges. The company's growth trajectory is not explicitly outlined in the available data, but the significant capital expenditure indicates a strategic investment in future operations. The outlook for the current fiscal year is not provided, but the company's financial performance suggests a stable position in the market. The risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, indicating a potential liquidity risk. The dilution risk is assessed as low, with no significant dilution potential reported in the data. The company's capital structure and liquidity position suggest that it is managing its financial obligations without immediate dilution pressures. Recent events and filings do not provide specific details on new developments or strategic initiatives for the company. The absence of recent significant events may indicate a stable but potentially less dynamic business environment for the company.

30-day price · MODD-20.11 (-25.9%)
Low$56.80High$82.31Close$57.39As of29 May, 00:00 UTC
Profile
CompanyModern Diagnostic & Research Centre Ltd
TickerMODD.BO
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Modern Diagnostic & Research Centre Ltd provides diagnostic and research services in the healthcare sector, primarily generating revenue through laboratory testing and related healthcare services.

Classification. The company is classified under the Healthcare economic sector, within the Healthcare Services & Equipment business sector, and the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Modern Diagnostic & Research Centre Ltd maintains a capital structure with a debt-to-equity ratio of 1.07, indicating a moderate reliance on debt financing. The company's liquidity position is assessed as medium, with a current ratio of 0.75, suggesting that its current liabilities exceed its current assets. Despite a net income of INR 89.68 million, the company reported negative free cash flow of INR 14,000, primarily due to a significant capital expenditure of INR 131.59 million. In terms of profitability, the company's return on equity (ROE) is 43.27%, and its return on assets (ROA) is 13.89%, both of which are strong indicators of efficient use of equity and assets. These figures suggest that the company is generating substantial returns relative to its equity and asset base, which is favorable compared to industry norms. The company's revenue is concentrated in a single business segment, as disclosed in its financial statements, with no geographic diversification provided in the available data. This lack of diversification may expose the company to higher operational and market risks if the primary segment faces challenges. The company's growth trajectory is not explicitly outlined in the available data, but the significant capital expenditure indicates a strategic investment in future operations. The outlook for the current fiscal year is not provided, but the company's financial performance suggests a stable position in the market. The risk assessment highlights a key flag: the company's net cash is negative after subtracting total debt, indicating a potential liquidity risk. The dilution risk is assessed as low, with no significant dilution potential reported in the data. The company's capital structure and liquidity position suggest that it is managing its financial obligations without immediate dilution pressures. Recent events and filings do not provide specific details on new developments or strategic initiatives for the company. The absence of recent significant events may indicate a stable but potentially less dynamic business environment for the company.
Key takeaways
  • The company has a strong return on equity and return on assets, indicating efficient use of capital.
  • The debt-to-equity ratio is moderate, suggesting a balanced capital structure.
  • The company's liquidity position is medium, with a current ratio below 1.
  • The company's revenue is concentrated in a single segment, which may increase operational risk.
  • The company has a significant capital expenditure, indicating investment in future growth.
  • The risk of dilution is low, and the company's liquidity position is stable.
  • --
  • ## RATIONALES
Financial snapshot
PeriodHA-latest
CurrencyINR
Revenue$779.5M
Gross profit$591.3M
Operating income$137.7M
Net income$89.7M
R&D
SG&A
D&A
SBC
Operating cash flow$137.3M
CapEx-$131.6M
Free cash flow-$14.0k
Total assets$645.7M
Total liabilities$438.5M
Total equity$207.3M
Cash & equivalents$7.8M
Long-term debt$220.9M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$207.3M
Net cash-$213.1M
Current ratio0.8
Debt/Equity1.1
ROA13.9%
ROE43.3%
Cash conversion1.5%
CapEx/Revenue-16.9%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Biotechnology · cohort 117 companies
MetricMODDActivity
Op margin17.7%5.6% medp25 -4.2% · p75 12.6%top quartile
Net margin11.5%2.8% medp25 -3.4% · p75 8.8%top quartile
Gross margin75.9%36.5% medp25 23.7% · p75 65.2%top quartile
CapEx / revenue-16.9%-4.9% medp25 -11.5% · p75 -2.0%bottom quartile
Debt / equity107.0%69.3% medp25 7.9% · p75 120.9%above median
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod financials
no public URL
2026-05-22 13:50 UTC#4712b830
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 15:03 UTCJob: 23df8595